Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)

Part of paid clinical trials in Saint Paul, Minnesota.

Sponsor
Deciphera Pharmaceuticals, LLC
Study ID
NCT07539090
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Healthy Participants

Eligibility Criteria

Sex
FEMALE
Age
18 Years - 55 Years
Healthy Volunteers
Accepted

Interventions

  • Vimseltinib — DRUG
    Administered orally
  • Combined Oral Contraceptive (COC) (ethinyl estradiol [EE]/levonorgestrel [LNG]) — DRUG
    Administered orally

Study Details

The main purpose of this study is to determine the effect of vimseltinib on pharmacokinetics of combined oral contraceptive (COC) (ethinyl estradiol/levonorgestrel) in healthy female participants. This study will last approximately 35 days.

Key Dates

Start date
Jun 5, 2026
Status verified
Jun 2026
Primary completion
Aug 31, 2026
Completion
Aug 31, 2026

Study Design

Enrollment
24 participants (estimated)
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Vimseltinib + Combined Oral Contraceptive (COC)
    Day 1 single dose of combined oral contraceptive (COC) (ethinyl estradiol \[EE\]/levonorgestrel \[LNG\]). Day 4 through 7, Day 11 and Day 14 single daily dose of Vimseltinib. Day 18 coadministration of COC (EE /LNG) with vimseltinib.

Primary Outcome Measure

Pharmacokinetics (PK): Maximum Observed Plasma Drug Concentration (Cmax) of EE and LNG [ Time Frame: Predose up to 72 Hours Post Dose ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Nucleus NetworkSaint PaulMinnesota55114
Jennifer Bookey
[email protected]
651-641-2900
Emmanuel Ferrer, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Saint Paul, MN

By research site
Nucleus Network· Saint Paul, MN

Related Studies